Acceptor‐Reactivity‐Controlled Stereoconvergent Synthesis and Immunological Activity of a Unique Pentasaccharide from the Cell Wall Polysaccharide of Cutibacterium acnes C7
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202405297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Tianhui Hao und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology, Carbohydrate-Based Drug Research Center, Institute of Materia Medica, Chinese Academy of Sciences, Shanghai…. Hauptthemen laut MEDLINE: Cell Wall, Oligosaccharides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Bacterial cell‐surface polysaccharides are involved in various biological processes and have attracted widespread attention as potential targets for developing carbohydrate‐based drugs. However, the accessibility to structurally well‐defined polysaccharide or related active oligosaccharide domains remains challenging. Herein, we describe an efficiently stereocontrolled approach for the first total synthesis of a unique pentasaccharide repeating unit containing four difficult‐to‐construct 1,2‐ cis ‐glycosidic linkages from the cell wall polysaccharide of Cutibacterium acnes C7. The features of our approach include: 1) acceptor‐reactivity‐controlled glycosylation to stereoselectively construct two challenging rare 1,2‐ cis ‐ManA2,3(NAc) 2 (β‐2,3‐diacetamido‐2,3‐dideoxymannuronic acid) linkages, 2) combination use of 6‐ O ‐ tert ‐butyldiphenylsilyl (6‐ O ‐TBDPS)‐mediated steric shielding effect and ether solvent effect to stereoselectively install a 1,2‐ cis ‐glucosidic linkage, 3) bulky 4,6‐di‐ O ‐ tert ‐butylsilylene (DTBS)‐directed glycosylation to stereospecifically construct a 1,2‐ cis ‐galactosidic linkage, 4) stereoconvergent [2+2+1] and one‐pot chemoselective glycosylation to rapidly assemble the target pentasaccharide. Immunological activity tests suggest that the pentasaccharide can induce the production of proinflammatory cytokine TNF‐α in a dose‐dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology, Carbohydrate-Based Drug Research Center, Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300350, China.
- School of Health and Life Sciences, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266113, China.
ORCID-Profile: Tiehai Li
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Hao, T., Feng, K., Jin, H., Li, J., Zhou, C., Liu, X., Zhao, W., Yu, F., & Li, T. (2024). Acceptor‐Reactivity‐Controlled Stereoconvergent Synthesis and Immunological Activity of a Unique Pentasaccharide from the Cell Wall Polysaccharide of Cutibacterium acnes C7. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202405297
Vancouver
Hao T, Feng K, Jin H, Li J, Zhou C, Liu X, et al. Acceptor‐Reactivity‐Controlled Stereoconvergent Synthesis and Immunological Activity of a Unique Pentasaccharide from the Cell Wall Polysaccharide of Cutibacterium acnes C7. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202405297
BibTeX
@article{Hao2024,
author = {Hao, Tianhui and Feng, Ke and Jin, Hongzhen and Li, Jiawei and Zhou, Chenkai and Liu, Xingbang and Zhao, Wei and Yu, Fan and Li, Tiehai},
title = {Acceptor‐Reactivity‐Controlled Stereoconvergent Synthesis and Immunological Activity of a Unique Pentasaccharide from the Cell Wall Polysaccharide of Cutibacterium acnes C7},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202405297}
}
EUVIMED